O besity increases the risk of heart failure (HF) 1 and cardiovascular death in the general population. 2 However, a significant survival benefit of obesity in patients with established HF has been extensively described in different settings: short-and long-term follow-up, acute and chronic HF, and in reduced and preserved ejection fraction. [3] [4] [5] [6] [7] The prevalence of overweight or obesity in patients with HF can reach about 35% to 45% 8, 9 when defined using body mass index (BMI).
Among weight indices, BMI has been shown to properly correlate with the thickness of the subcutaneous fat layer 10 and has been rapidly adopted as the primary obesity index in HF. Other parameters used for measuring body composition (waist circumference, skinfold estimates of percentage of body fat, DEXA, and bioelectrical impedance analysis) have also demonstrated an independent relationship with mortality in HF patients, [11] [12] [13] although none has proved to be clearly superior to BMI; thus, the use of BMI in HF remains routine clinical practice. Despite the potential benefits of weight loss (WL) in obese and overweight patients, this recommendation may not apply to patients with HF. Indeed, both the American College of Cardiology/American Heart Association and the European Society of Cardiology guidelines in HF do not provide conclusive recommendations about WL. 14, 15 Moreover, the prognostic impact of WL in obese patients with HF is not completely known, despite possible beneficial effects of WL on hemodynamics, cardiac structure, diastolic function, and even systolic function. 16 Robust evidence regarding the relation of WL and long-term prognosis in patients with chronic HF is missing. [17] [18] [19] Accordingly, our aim was to analyze the prevalence of WL over a 1-year follow-up period and its impact on mortality in a large, real-life, outpatient population with HF, with special attention to obese patients.
Subjects and Methods

Design and Study Population
All consecutive, ambulatory patients referred between August 1, 2001 and September 30, 2011 to a structured HF clinic at a university hospital, irrespective of etiology, with available weight data at the first visit and at a 1-year follow-up visit were included in an outpatient setting. The criteria for clinical practice referral to the HF clinic have been reported elsewhere. 20, 21 Briefly, the criteria were HF with at least one hospitalization and/or reduced left ventricular ejection fraction (LVEF) of <40%. Most patients were referred from cardiology and internal medicine departments, and fewer were from the emergency room/short-stay unit or other hospital departments. Less than 10% of patients were admitted to the HF unit due to asymptomatic, reduced LVEF after acute myocardial infarction. BMI was analyzed according to weight and height using the formula weight (kg)/(height [m]) 2 and obese (BMI ≥30 kg/m 2 ). Significant WL was defined as a loss of ≥5% from the initial weight (ie, baseline) to end of first year of follow-up. All patients were seen regularly during follow-up visits at the HF clinic according to their clinical needs. The follow-up visit schedule (nurses and physicians) has been reported elsewhere. 21, 22 Losing weight with dietary restrictions was not routinely advised for overweight, nor for the majority of obese patients, although a healthy diet and physical exercise is always recommended. Only some morbid obese patients were managed by the Endocrinology and Nutrition Service. The nutritionist at the HF Unit was primarily involved in undernourished patients with lack of appetite. Patients in NYHA class II to IV were evaluated by a rehabilitation physician and an exercise program was offered. Nevertheless, less than one third of the patients in the present study actually participated in such an established program. All patients provided written consent for analytical samples and the use of their clinical data for research purposes. The study was performed in compliance with laws protecting personal data in accordance with the international guidelines on clinical investigation of the World Medical Association's Declaration of Helsinki, it was approved by the local ethics committee, and all patients signed informed consent. At the first visit, we recorded the patient's demographic characteristics, baseline clinical status, physical examination data, and treatment following a standardized protocol.
Mortality Assessment
Death from all causes was the main outcome. 
Results
Of 1322 patients admitted to the HF Unit, a total of 1000 patients (72.7% men; mean age 65.8AE12.1 years) were included in the study. Causes for noninclusion were as follows: 139 patients died during the first year of follow-up, 152 did not attend the 1-year visit, and 31 had no weight available (wheelchair or impossibility to stand up). The demographic and clinical characteristics of the patients are summarized in Table 1 . The patients were predominantly ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; CRT, cardiac resynchronization therapy; DCM, dilated cardiomyopathy; HF, heart failure; hs-CRP, high-sensitivity C-reactive protein; hs-TnT, high sensitivity cardiac troponin T; HYP, hypertension; ICD, implantable cardiac defibrillator; IHD, ischemic heart disease; LVEF, left ventricular ejection fraction; MEDS, medications; MRA, mineralocorticoid receptor antagonist; NTproBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association; ST2, high-sensitivity soluble ST2; STfR, soluble transferrin receptor; WL, weight loss. *MeanAESD.
male, with a median duration of HF of 10.5 months (Q1-Q3 2-48 months), and a mean LVEF of 32.4AE12.6%. One hundred seventy patients (17%) experienced significant WL during the first year of follow-up. Figure 1 illustrates the percentage of patients with WL ≥5%, showing a significantly higher rate in overweight and obese patients. Table 1 shows the clinical differences between patients with and without significant WL. In addition to sex, most were related to HF severity and treatment. In a limited sample of patients, we have data on biomarkers, without differences between both groups; only high-sensitivity troponin T tended to be higher in patients with significant WL (P=0.05, Table 1 ).
After 3 years of follow-up from the first visit (ie, 2 years after the second weight assessment), 174 patients (17.4%) died-121 from cardiovascular causes (54 worsening HF, 30 sudden death, 11 acute myocardial infarction, 5 stroke, and 21 other), 40 from noncardiovascular causes, and 13 from unknown causes. Mortality in significant WL patients was significantly higher than in patients without significant WL (27.6% versus 15.3%, P<0.001). This was basically due to cardiovascular mortality (20.0% versus 10.9%, respectively, P=0.01), whereas differences in noncardiovascular mortality were nonsignificant (6.0% versus 3.7%, respectively, P=0.16). Of note, death due to worsening HF was 11.2% and 4.2%, respectively, P<0.001.
In Figure 3 shows adjusted survival curves for cardiovascular death relative to the presence or absence of significant WL for nonobese and obese patients. Tables 4 and 5 show Cox regression multivariable analyses for all-cause and cardiovascular death, respectively, using standardized WL as continuous variable (with 1 SD decrease).
Discussion
The main conclusion of this study may seem perplexing, which is that significant WL might be not beneficial even in obese patients with HF. This finding may, in part, provide a rationale for the obesity paradox in HF, which is extensively described, [3] [4] [5] [6] [7] A few reports with small sample populations exist on the effect of intentional weight reduction on quality of life and cardiac function in patients with HF. Mariotti et al evaluated the impact of a planned body weight reduction plan on quality of life and cardiac function in 34 obese and overweight chronic HF patients through a 6-month nutritional and physical activity program. Those patients who achieved a loss of at least 3 kg (about 3.2% of WL) showed a significant improvement in LVEF and mean NYHA functional class and quality of life. The study did not evaluate mortality. 28 Another small randomized clinical trial evaluated the benefit of losing weight via a lipase inhibitorassisted diet in 21 severely obese patients. Significant WL (5% absolute reduction in body weight) and improvement in the 6-minute walking test and functional class were observed in the treated group at 12 weeks. 29 Again, no analysis of mortality could be performed due to the small sample size and short follow-up. Data on unintentional WL in obese patients are even scarcer. In a post-hoc analysis of the SOLVD trial, Anker et al 30 were the first to suggest that any WL independent of the patients' weight at baseline is related to poor survival, although no specific comment on obese patients was reported. to ours. As in Val-Heft, we found that significant WL (using similar criteria) was associated with female sex, worse NYHA functional class, higher BMI, and less use of b-blockers. It has been suggested that b-blockers may exert anticachexic effects by inhibiting catecholamine-induced lipolysis. 32 We also found an association between significant WL and treatment with mineralocorticoid receptor antagonists and loop diuretics-the latter of which was also observed in GISSI-HF-and with digoxin, treatments all associated with the severity of HF. Whether biomarkers are useful to mirror or as surrogate markers of WL is unknown. Song et al 33 showed an independent association between high-sensitivity C-reactive protein and unintentional WL in 243 patients with HF enrolled during an index hospitalization for HF exacerbation (OR, 1.49; 95% CI, 1.15-1.92). In the Val-HeFT "biomarker" substudy, both Nterminal pro-brain natriuretic peptide and high-sensitivity Creactive protein were associated with significant WL. 31 In our study, we found no association between significant WL and any of these 2 biomarkers or with ST2 and soluble transferrin receptor. Only high-sensitivity troponin T tended to be higher in patients with significant WL (P=0.05), which may eventually indicate myocyte damage caused by WL itself. From a prognostic point of view, significant WL was independently associated with mortality, with an increased risk of death of 20% (GISSI-HF) to 150% (Val-HeFT). 31 In our study, the risk of death for significant WL after adjustment in the multivariable model was 89% higher. Very remarkably, among obese patients (BMI ≥30 kg/m 2 ), significant WL was associated with an even higher risk of death (138% increase) than in nonobese patients (83% increase). This finding was very unexpected, even more so considering that low-weight patients were not excluded from the analysis. In an analysis of the CHARM study, 34 those patients with 5% or greater WL in 6 months had a >50% increase in hazard both for cardiovascular and for other causes of death compared to those with stable weight. The impact of WL on mortality was not significantly related to BMI, although WL carried a particularly high risk in patients who were already lean at study entry. In our study, in contrast, cardiovascular mortality was almost doubled and the patients with highest adjusted hazard of death were the obese patients. Remarkably, in our study the higher mortality rate observed in patients with significant WL was mainly caused by worsening HF. On the other hand, although noncardiovascular death was non-negligible in our series (23%), it was nonsignificantly higher in patients with significant WL. Nevertheless, WL was not associated with an adverse prognosis in all HF settings. The RICA Registry 35 analyzed weight changes in 731 patients admitted with acute HF during a 1-year follow-up. One hundred fifty-two patients (20.8%) experienced WL. No differences were observed in terms of mortality and rehospitalization between the 2 groups. These results, observed in the acute setting in decompensated patients, are in disagreement with our data and those of others obtained in ambulatory, stable patients without overt congestion. Finally, it has been suggested that incorporating physical activity and exercise training into a purposeful WL program might be of benefit in patients with HF. 36 In the HF-ACTION study, nonsignificant reductions in all-cause mortality and hospitalization were observed across BMI categories, although no association with WL was identified. 9 Further studies are needed to ascertain whether this strategy might improve outcomes in obese patients with HF.
Limitations
The present data are based on BMI-based WL without further anthropometric characterization (muscle or fat mass wasting assessments), and we cannot fully ascertain whether WL was in part intentional or nonintentional. However, the result of intentional WL is difficult to address, and most of the analyses performed in HF trials included both intentional and nonintentional WL as we did. We defined significant WL as a loss of ≥5% of the initial weight during the first year of follow-up, as previously described. 31, 34, 35 This cut-off can be considered arbitrary as were all the definitions used in previous studies; however, no definite cut-off exists. Ideally, dry weight should be used to track WL. We only found statistically significant differences between patients with and without significant WL in NYHA functional class, sex, and baseline BMI; nevertheless, we cannot completely discard the possibility that they were sicker from the start, since significant WL is just a marker of such a situation without playing a causative role. Further studies are needed to fully clarify the putative causative role of significant WL in outcomes. We have no data on what happened to weight during follow-up between year 1 and year 3 or the time of death, and we only analyzed weight loss during the first year of follow-up. In the present study, we focused on stable outpatients, but whether subclinical congestion may have influenced our results remains a caveat. Although our population is a general population attending a HF unit, the unit is located at a tertiary university hospital and the cohort patients are mainly male and of ischemic etiology, with the great majority having had a hospital admission in the previous year or a depressed LVEF. Therefore, we cannot disregard the possibility of bias due to selection of patients who may not necessarily represent the general HF population.
Conclusions
Weight loss of ≥5% during 1 year in ambulatory HF patients was associated with an ominous prognosis in the subsequent 2 years. This association was even more apparent in obese patients. Significant WL might not be beneficial in obese HF patients, and indiscriminate advice to lose weight in this population might not be indicated. Further studies are needed to ascertain whether WL and the mode of WL achievement might ultimately be beneficial in obese or even very obese patients with HF.
